Upstream transcription factor 1 prompts malignancies of cervical cancer primarily by transcriptionally activating p65 expression

WEN WANG¹, SHUJUAN YAO¹, HONGJING JIANG¹, JING DONG¹, XIUJUAN CUI¹, XIANGYU TIAN², YANYAN GUO³ and SHIQIAN ZHANG⁴

Departments of ¹Obstetrics and Gynecology, and ²Medical Imaging, Tengzhou Central People’s Hospital, Tengzhou, Shandong 277500; ³Department of Obstetrics and Gynecology, Shandong Police Hospital, Jinan, Shandong 250001; ⁴Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China

Received August 10, 2016; Accepted July 20, 2017

DOI: 10.3892/etm.2018.6758

Abstract. Cervical cancer is the third-most common cause of female cancer-related mortality worldwide. In cervical cancer, aberrant activation of nuclear factor (NF)-κB signaling is widely reported. However, the transcriptional regulation of NF-κB signaling remains unclear. The present study aimed to explore the underlying mechanism in which NF-κB signaling was activated in cervical cancer cells. Initially, the expression of p65 was demonstrated to be markedly enhanced in grade II, III or IV cervical cancer tissues compared with that of normal cervical tissues, indicating that p65 expression was correlated with tumor grade. In HeLa and CaSki cells, overexpression of p65 markedly enhanced cervical cancer cell invasion and migration. Further experiments demonstrated that p65 overexpression significantly increased the phosphorylation levels of protein kinase B (AKT) and p38. Dual luciferase reporter and chromatin immunoprecipitation assays demonstrated that USF1 was able to bind the promoter region of p65, thereby enhancing the transcriptional activation of p65. Notably, when p65 was silenced, the phosphorylation levels of AKT and p38 were suppressed even in cells transfected with adenovirus vectors expressing upstream transcription factor 1 (USF1). These data indicated that USF1 prompted cervical cancer progression primarily by transcriptionally activating p65. In conclusion, the present study demonstrated that USF1 was able to activate the transcription of p65, thereby enhancing the malignancy of cervical cancer cells.

Introduction

Cervical cancer is the third most common cause of female cancer-related mortality and increased at a mean annual rate of 0.6% between 1980 and 2010 (1,2). At present, typical therapies for cervical cancer include surgery, radiotherapy and/or chemotherapy, alone or in combination (3,4). However, the recurrence and metastasis of cervical carcinoma remain problematic in clinical practice (5,6). Therefore, it is important to explore the underlying mechanisms that regulate the migration and invasion of cervical cancer cells.

Nuclear factor (NF)-κB induces a variety of biological processes via transcriptional gene control of key components in different signaling pathways (7,8). The complexes of NF-κB include five different subunits, namely RelA/p65, RelB, c-Rel, p50 and p52, which are able to form distinct homodimers and heterodimers (9,10). Classical NF-κB is a heterodimer that consists of the DNA binding subunit p50 and the transactivation subunit RelA/p65 (11). In the normal status, NF-κB remains in the cytoplasm and translocates into the nucleus following exposure to the stimuli, including inflammatory responses and hypoxia, thereby enhancing abnormal cell proliferation and survival (12). In cervical cancer, aberrant activation of NF-κB signaling is widely reported (13,14). However, the transcriptional control of NF-κB signaling remains unclear.

As a member of the basic helix-loop-helix leucine zipper (bHLH-LZ) family, the upstream transcription factor 1 (USF1) is widely associated with the transcription of many genes (15,16). Through binding the E-box motifs in the promoter region, USF1 is able to activate the transcription of target genes in the form of a homodimer or a heterodimer (USF1/2) (15). For instance, various genes associated with lipid and glucose metabolism have been reported to be modulated by USF1 (15-17). To the best of our knowledge, the expression and potential functional role of USF1 in cervical cancer has not been reported previously.

In the present study, the expression of USF1 was explored in cervical cancer. It was demonstrated that USF1 expression was markedly enhanced in grade II, III, and IV cervical cancer tissues compared with that of normal cervical tissues. Further experiments indicated that two E-box motifs were located at the promoter region of RelA/p65. A chromatin
immunoprecipitation (ChIP) assay demonstrated that USF1 was able to activate the transcription of RelA/p65, thereby enhancing the malignant invasion and migration phenotype of cervical cancer cells.

Materials and methods

Ethics statement. Primary human cervical cancer patient specimens were obtained from patients and informed consent was obtained under protocols approved by Review Boards of Shandong University (Jinan, China). Biopptic samples from patients with cervical cancer were frozen in liquid nitrogen and stored at -80°C. The present study was approved by the Ethics Committee of Tengzhou Central People's Hospital (Tengzhou, China). A total of 10 cervical cancer tissues (age, 52.3±12.5) and 5 normal adjacent para-cervical cancer tissues (age, 48.7±11.6, female) were collected from patients at the Tengzhou Central People's Hospital (Tengzhou, China) between November 2012 and December 2012. The tissues were analysed to determine the clinical staging and clinicopathological characteristics of each case of cervical cancer. Diagnoses were made in accordance with the altered International Federation of Gynecology and Obstetrics staging system (18). There was 1 patient at Stage I, 3 patients at Stage II, 3 patients at Stage III and 3 patients at stage IV. All patients enrolled in the present study were diagnosed with gynaecological tumours. The inclusion criteria for the present study were as follows: i) Pathological diagnosis confirmed by a minimum of 2 pathologists; ii) patient received a thorough pre-treatment evaluation, including a detailed medical history, physical examination, whole blood cell count, liver and kidney function tests, imaging examination (chest X-ray, color Doppler ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography), electrocardiogram, comprehensive assessment of electronic colposcopy for vulva, vagina, cervix and cystoscopy. Colonoscopy was also included in the presence of a clinical indication; iii) the clinical stage of cervical cancer was determined by 3 gynecologic-oncologists; iv) patients had complete medical history, physical examination, whole blood cell count, liver and kidney function tests, and equal quantities of DNA were used as the template. The precipitated DNA was amplified with p65-specific primers. The primers specific to the USF1 binding sites on the p65 promoter were as follows: Forward, 5'-GA TCC CCA GAG GGT TT-3'. Quantitative PCR was performed using SYBR-Green PCR Master mix (Roche Diagnostics, Basel, Switzerland) on an Applied Biosystems ViiA 7 Real-time PCR system (Thermo Fisher Scientific, Inc.). The final reaction volume was 10 µl and contained 5 µl SYBR-Green PCR Master mix (2X), 0.5 ml forward and 0.5 µl reverse primers (10 mM), 2 ml cDNA and 2 µl double-distilled water. The procedure used for qPCR was as follows: 95°C for 10 min followed by 50 cycles of 95°C for 10 sec, 55°C for 10 sec, 72°C for 5 sec; 99°C for 1 sec; 59°C for 15 sec; 95°C for 1 sec; then cooling to 40°C. Comparison of input, USF1 pulldowns were reported as the average according to the manufacturer's protocol (EMD Millipore).

Cell lines. The two human cervical cancer cell lines, including HeLa and CaSki, and 293T cells were obtained from American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO₂. All of the above materials were purchased from GE Healthcare Life Sciences, (Logan, UT, USA).

Construction of adenovirus vectors. Adenovirus vectors overexpressing USF1 (Ad-USF1), inhibiting USF1 (Ad-USF1i) or the negative control (Ad-NC) were constructed by Shanghai Genechem Co., Ltd. (Shanghai, China). In brief, HeLa cells were seeded at a density of 10⁴ cells/well for 24 h. Ad-USF1, Ad-USF1i or Ad-NC was subsequently transfected into HeLa cells for 48 h at 37°C. The RNA was collected after the above adenovirus vectors were transfected into HeLa cells for 48 h and used for further analysis.

ChIP. ChIP assay was performed using the Chromatin Immunoprecipitation Assay kit (EMD Millipore, Billerica, MA, USA). Briefly, the nucleic DNA was extracted from cells and sonicated into 200-1000 bp. Precleared chromatin was immunoprecipitated with anti-USF1 (1:100; ab180717) and immunoglobulin G (1:100; ab172730) (both Abcam, Cambridge, UK) antibodies according to the manufacturer's protocol. Immunocomplexes were added into 50 µl protein A/G-Sepharose beads and purified with Qiagen (Qiagen GmbH, Hilden, Germany) polymerase chain reaction (PCR) purification columns. The DNA of HeLa and CaSki cells was quantified on a NanoDrop™ ND3300 (Thermo Fisher Scientific, Inc., Waltham, MA) using a Quant-iT Picogreen dsDNA Assay kit (Invitrogen; Thermo Fisher Scientific, Inc.) and equal quantities of DNA were used as the template. The precipitated DNA was amplified with p65-specific primers. The primers specific to the USF1 binding sites on the p65 promoter were as follows: Forward, 5'-GTACCAGAGGT GATTCTGC-3'; and reverse 5'-AAGCTACTCTGGATTGCC TT-3'. Quantitative PCR was performed using SYBR-Green PCR Master mix (Roche Diagnostics, Basel, Switzerland) on an Applied Biosystems ViiA 7 Real-time PCR system (Thermo Fisher Scientific, Inc.). The qPCR was performed using SYBR-Green Supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in a Bio-Rad iCycleriQ PCR. The primers used were as follows: 5'-ATC CCC CAT CTC CAC GCT TCT T-3' and reverse 5'-AGAGCCCTCTGTAGGGCAGG-3'; GAPDH forward 5'-GAGAGGCTGGGGCCTCATT-3' and reverse 5'-AGTGA TGG CAT GGACTGTG-3'.

RNA extraction and reverse transcription-quantitative (RT-q) PCR. The total RNA from primary human cervical cancer tissues was isolated using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. The total RNA was reverse transcribed into cDNA using a TaqMan RNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). qPCR was performed using SYBR-Green Supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in a Bio-Rad iCycleriQ real-time PCR detection system as described above. GAPDH was used as the internal control. The primers used were as follows: P65 forward, 5'-ATC CCC CAT CTC CAC GCT TCT T-3' and reverse 5'-AGAGCCCTCTGTAGGGCAGG-3'; GAPDH forward 5'-GAGAGGCTGGGGCCTCATT-3' and reverse 5'-AGTGA TGG CAT GGACTGTG-3'.

Protein extraction and western blot analysis. Proteins samples were extracted from primary human cervical cancer tissues or normal adjacent para-cervical cancer tissues and cultured HeLa and CaSki cells in radioimmunoprecipitation assay
buffer (1% TritonX-100, 15 mmol/l NaCl, 5 mmol/l EDTA and 10 mmol/l Tris-HCl; pH 7.0; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) supplemented with a protease and phosphatase inhibitor cocktail (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany.) A bicinchoninic protein assay kit (Pierce; Thermo Fisher Scientific, Inc.) was used to determine the protein concentration. Equal quantities of protein (15 μg) were separated by 10% SDS-PAGE and electrophoretically transferred to a PVDF membrane. Following blocking with 8% milk in PBS with Tween-20 (pH 7.5) for 2 h at room temperature, membranes were incubated with the following primary antibodies at 4°C overnight: Anti-USF1 (cat. no. ab180717; 1:1,000, Abcam), anti-p-p65 (cat. no. ab86299; 1:1,000; Abcam), anti-p65 (cat. no. ab180717; 1:1,000; Abcam), anti-phosphorylated (p)-protein kinase B (AKT; cat. no. 13038; 1:1,000), anti-AKT (cat. no. 5084; 1:1,000), anti-p-p38 (cat. no. 8632; 1:1,000.), anti-p38 (cat. no. 8690; 1:1,000) and anti-GAPDH (5174; 1:1,000) (all Cell Signaling Technology, Inc., Danvers, MA, USA). Following several washes with TBST the membranes were incubated with horserasish-peroxidase (HRP)-conjugated goat anti-rabbit (cat. no. ZB-2306; 1:5,000; OriGene Technologies, Inc., Beijing, China) for 2 h at room temperature and then washed. Immunodetection was performed using the Immobilon Western Chemiluminescent HRP Substrate (cat. no. WBKLS0500; EMD Millipore) enhanced chemiluminescence detection system according to the manufacturer's protocol. The house-keeping gene GAPDH was used as the internal control. ImageJ 1.43b software (National Institutes of Health, Bethesda, MD, USA) was used for density analysis.

**Invasion and migration assays.** HeLa and CaSki cells were seeded in DMEM culture in the top chamber of each Transwell insert (BD Biosciences, San Jose, CA, USA) at 1.0x10⁵ cells/well with 8.0-mm pores for the migration assay. For the invasion assay, 2.0x10⁵ cells were cultured in DMEM culture in the upper chamber of a Transwell insert (BD Biosciences) at 37°C for 24 h that was pre-coated with 0.2% Matrigel (Osciient Pharmaceuticals Corporation, Waltham, MA, USA) at 37°C. As a chemoattractant, 10% fetal bovine serum was added to the DMEM culture medium in the lower chamber. Then, Ad-p65 or Ad-NC/Ad-USF1 or Ad-NC was placed into the lower chamber at 37°C for 24 h. Following incubation for 24 h at 37°C, remaining cells in the upper chamber were removed using cotton swabs, and those which had migrated or invaded through the membrane were stained with a dye solution containing 20% methanol and 0.1% crystal violet at 37°C for 15 min. Cells were subsequently imaged under a light microscope (magnification, x40; Olympus Corporation, Tokyo, Japan) and 10 individual fields were randomly chosen and counted per insert. The results are presented as the mean of three separate experiments.

**Promoter reporter analysis.** The promoter region of p65 was amplified from the genomic DNA of HeLa cells by PCR. The pGL3 Basic vector (Promega Corporation, Madison, WI, USA) and the amplified fragments were digested with XhoI/KpnI (New England BioLabs, Inc., Ipswich, MA, USA) and purified by 2% agarose gel electrophoresis. The reaction mix included 10X buffer (including Mg²⁺), 5 μl; 2.5 mM dNTP, 2 μl; 10 μM forward primer, 1 μl; 10 μM reverse primer, 1 μl; template, 2 μl; Taq DNA polymerase, 0.5 μl (Takara Bio, Inc., Otsu, Japan); ddH2O 38.5 μl (Takara Bio, Inc.) The procedure included 94°C for 5 min; 30 cycles of 94°C for 30 sec, 55°C for 30 sec, 72°C for 1 min; and 72°C for 5 min. The primer sequences used for the PCR reaction were as follows: p65 forward, CAAGAGGCCCCATTAGCTC CC; and p65 reverse, CAAGAGGCCCCATTAGCTCC. The digested fragment was then inserted into the pGL3 vector using a Dual-luciferase Reporter Assay system (Promega, Corporation) according to the manufacturer's protocols. Normalized luciferase data (firefly/Renilla) was compared with the empty pGL3-Basic vector.

**Immunohistochemistry.** Harvested primary human cervical cancer tissues or normal adjacent para-cervical cancer tissue samples were fixed in 4% phosphate-buffered neutral formalin at room temperature for 20 min, embedded in paraffin and cut into 5-μm thick sections, followed by deparaffinization, rehydration in a descending series of alcohol and microwave-heating in sodium citrate buffer (Beijing Solarbio Science & Technology Co., Ltd.) at 100°C for 30 min for antigen retrieval. Sections were subsequently incubated with 0.3% hydrogen peroxide/phosphate-buffered saline for 30 min. The sections were incubated with a primary anti-p65 antibody (1:100) at a 1:50 dilution and 4°C overnight. Detection of the primary antibody was performed via incubation with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (ZDR-5036; OriGene Technologies, Inc.) for 1 h at room temperature and visualized with a 3,3'-Diaminobenzidine substrate. Stained cells were counted in 5 random fields using an Olympus CK40 light microscope (magnification, x40; Olympus Corporation).

**Transient transfection.** Initially 6x10⁵ cells were equally seeded in 6-well plates with 2 ml DMEM medium containing serum and antibiotics as described above. Small interfering RNA targeting p65 (5'-CGATTTCCTAACTCCAGAGT-3') or negative control (5'-TTCTCCGAACGTTCACGTT-3') were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). Simultaneously, siRNA-p65 or -NC were mixed with HiPerFect transfection reagent (Qiagen GmbH, Hilden, Germany) and incubated at room temperature for 10 min. Each complex was subsequently transfected into two wells containing the HeLa cells for 48 h at 37°C at a final concentration of 10 nM in the presence or absence of Ad-USF1. To further evaluate whether USF1 exerts its role through p65, Ad-USF1 or Ad-NC was transfected into HeLa cells for 24 h. Then, si-p65 or si-NC was transfected into the above cells with Ad-USF1 or Ad-NC for another 48 h as described above. Following transfection for 48 h the cells were collected for further analysis.

**Statistical analysis.** Data were presented as the mean ± standard deviation from three independent experiments. Statistical
analysis was performed using Student's t-test for comparisons between two groups, and one-way analysis of variance followed by a post hoc Tukey's test were used for comparisons of two more groups, using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

**Overexpression of p65 in cervical cancer tissues.** Initially, the expression of p65 was evaluated in cervical cancer tissues. Compared with normal cervical tissues, the expression of p65 was markedly higher in cervical cancer tissues (Fig. 1A). Furthermore, compared with normal tissues the expression of p65 was markedly enhanced in grade II, III or IV cervical cancer tissues, whereas less obvious changes were observed in grade I cervical cancer tissues (Fig. 1A), which suggests that p65 expression was correlated with tumor grade. Furthermore, the mRNA level of p65 was also significantly enhanced in cervical cancer tissues (Fig. 1B) compared with controls (data not shown).

**p65 enhances cervical cancer cell invasion and migration.** The role of p65 in cancer cell invasion and migration was explored. Ectopic expression of p65 was introduced in HeLa and CaSki cells using adenovirus vectors overexpressing p65 (Ad-p65) compared with that of controls (Ad-NC). It was demonstrated that transfection with Ad-p65 in HeLa and CaSki cells markedly increased cancer cell invasion and migration capacities (Fig. 2A). Furthermore, the downstream effectors, including AKT and p38 signaling, were also investigated. As shown in Fig. 2B, overexpression of p65 significantly enhanced the phosphorylation levels of AKT and p38 in HeLa cells, which suggests an oncogenic role of p65 in cervical cancer cells.

**USF1 activates p65 expression.** Whether USF1 was able to activate the transcription of p65 was also investigated. In multiple genes, an enhancer (E)-box lies within the promoter region to provide a binding site for members of the basic helix-loop-helix (bHLH) transcription factor family and promotes the transcription of the downstream gene (19). USF1 belongs to the eukaryotic evolutionary conserved basic-Helix-Loop-Helix-Leucine Zipper transcription factor family and demonstrates higher binding affinity for E-box elements (20). Notably, two E-box elements were identified in the promoter region of p65 (Fig. 3A). Subsequently the expression of USF1 in cervical cancer tissues was evaluated. Compared with normal cervical tissue, the expression of USF1 was markedly enhanced in the cervical cancer tissues (Fig. 3B). Subsequently, the promoter region of p65 was cloned into the pGL3 Basic reporter vector. A dual luciferase reporter assay demonstrated that inhibition of USF1 was able to significantly decrease the relative luciferase reporter activity of pGL3-p65 compared with blank vector (Fig. 3C). Furthermore, a ChIP assay demonstrated that the knockdown of USF1 expression in HeLa cells significantly reduced the interaction between USF1 and the p65 promoter (Fig. 3D), whereas the over-expression of USF1 significantly enhanced its interaction with p65 promoter (Fig. 3E). These data suggested that USF1 was able to bind the promoter region of p65.

**Overexpression of USF1 enhances cervical cancer cell invasion and migration by transcriptionally activating p65.** The functional role of USF1 on HeLa and CaSki cancer cell migration and invasion was evaluated. It was demonstrated that migration and invasion capacities were markedly increased in cervical cancer cells transfected with Ad-USF1 compared with that of Ad-NC (Fig. 4A). In addition, the protein level of p65 was significantly enhanced when USF1 was upregulated in HeLa cells compared with controls (Fig. 4B). Furthermore, the expression of p65 was also significantly enhanced in HeLa cells overexpressed with USF1 (Fig. 4B). To further determine
Figure 2. p65 enhanced cell invasion and migration capacities. (A) Invasion and migration assays. (B) Western blot analysis of AKT and p38 activation when p65 was overexpressed. Data are presented as the mean ± standard deviation of three independent experiments. *P<0.05 vs. Ad-NC. Ad-NC, control adenovirus; Ad-p65, adenovirus vectors overexpressing p65; p, phosphorylated; AKT, protein kinase B.

Figure 3. USF1 was able to activate the expression of p65. (A) Two E-boxes were identified in the promoter region of p65. (B) The expression of USF1 was markedly enhanced in cervical cancer tissues. (C) Dual luciferase reporter assay demonstrated that silencing USF1 was able to significantly reduce the relative luciferase reporter activity of pGL3-p65 compared with blank vector. (D) ChIP assay demonstrated that the knockdown of USF1 expression in HeLa cells reduced the interaction between USF1 and the p65 promoter. (E) ChIP assay demonstrated that the over-expression of USF1 enhanced its interaction with p65 promoter. Data are presented as the mean ± standard deviation of three independent experiments. **P<0.01 vs. pGL3; ***P<0.001 vs. pGL3; *P<0.05 vs. Ad-NC; USF1, upstream transcription factor 1; ChIP, chromatin immunoprecipitation; TSS, transcription start site; RLU, relative light units; Ad-NCi, negative control adenovirus vectors for inhibiting gene expression; Ad-USF1i, adenovirus vectors for inhibiting USF1; Ad-NC, control adenovirus; Ad-USF1, adenovirus vectors overexpressing USF1.
whether USF1 exerts its role through p65, the expression of p65 was silenced in HeLa cells. As shown in Fig. 4C, when p65 was inhibited, the phosphorylation levels of AKT and p38 were significantly suppressed even in cells transfected with ad-USF1 (Fig. 4C). These data suggest that USF1 induced cervical cancer cell migration and invasion mainly via p65.

Discussion

Cervical cancer is regarded as the third-most common cause of cancer-related mortality among women worldwide (21). Recent studies have demonstrated that metastasis, rather than the original tumor, is the predominant cause of cancer-related mortality; therefore, it is of great importance to suppress cancer cell metastasis (22,23).

Abnormal activation of NF-κB serves a key role in modulating cancer-cell migration and invasion (24). In cervical cancer, constitutive NF-κB activation has been demonstrated to enhance tumor progression and is suggested to be correlated with poor prognosis (25). Typically, p65 forms a heterodimer with p50 and remains in the cytoplasm. Following exposure to stimuli including, hypoxia or inflammation the inhibitory subunit is degraded and the heterodimer of NF-κB is transported from the cytoplasm into the nucleus (26). Through
binding to the xB site in the promoter region of many target genes, NF-κB is associated with numerous target genes (27). It has been previously reported that suppression of NF-κB activity is able to inhibit cancer cell migration, invasion, angiogenesis, and metastasis (28,29). In the present study, it was demonstrated that p65 was upregulated in cervical cancer tissues compared with normal cervical tissues. In accordance with previous studies, it was demonstrated that overexpression of p65 markedly enhanced cancer cell migration and invasion. Notably, NF-κB is known to activate p38 mitogen-activated protein kinase (MAPK) and AKT, which subsequently regulate the expression of various genes associated with cancer cell invasion (30). In the present study, western blot analysis indicated that overexpression of p65 significantly enhanced the phosphorylation level of p38 MAPK and AKT, thereby prompting the migration and invasion process.

USF1 is a ubiquitous transcription factor of the bHLH-LZ family that is widely associated with lipid and glucose metabolism (31,32). However, whether it is associated with the progression of cervical cancer remains to be elucidated. In the present study, the expression of USF1 in cervical cancer tissues was explored and it was demonstrated to be significantly upregulated compared with normal cervical tissues. Notably, two conserved E-box elements were identified in the promoter region of p65. ChIP assay and luciferase reporter assay demonstrated that USF1 was able to bind to the promoter region of p65 and significantly activate the transcription of p65 in cervical cancer cells. Further experiments demonstrated that USF1 was also able to enhance HeLa cell migration through AKT and p38 activation. Notably, it was determined that USF1-mediated activation of AKT/p38 signaling was partially abolished by p65 silencing, which suggests that USF1 enhanced the malignancies of cervical cancer cells primarily by transcriptionally activating p65 expression.

To the best of our knowledge, the present study demonstrated for the first time that USF1 expression was enhanced in cervical cancer tissues. As a ubiquitously expressed transcription factor, USF1 was able to bind to the promoter region of p65 and transcriptionally activate the expression of p65, thereby enhancing the migration and invasion of cervical cancer cells.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Jining Medical University teacher research support fund (grant no. JY2017FS033).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WW performed the experiments and analyzed the data. SY, HJ, JD, XC, XT and YG performed part of RT-qPCR. SZ designed the experiments, analyzed the data and gave final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Review Board of Shandong University and written informed consent was obtained from all patients prior to their inclusion.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ and Naghavi M: Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 378: 1461-1484, 2011.
2. Bian ML, Cheng YJ, Ma L, Cong X, Liu J, Chen Y and Chen X: Evaluation of the detection of 14 high-risk human papillomaviruses with HPV-16 and HPV-18 genotyping for cervical cancer screening. Exp Ther Med 6: 1332-1336, 2013.
3. Chao A, Lin CT and Lai CH: Updates in systemic treatment for metastatic cervical cancer. Curr Treat Options Oncol 15: 1-13, 2014.
4. Lu X, Wu L, Liu Z, Xie L and Wang S: Peripheral blood mono-nuclear cells inhibit proliferation and promote apoptosis of HeLa cells following stimulation with Bacillus Calmette-Guérin. Exp Ther Med 5: 561-566, 2013.
5. Narthinanthar A, Thanaprapasr K, Udomsubpayakul U and Thanaprapasr D: Age and survival of cervical cancer patients with bone metastases. Asian Pac J Cancer Prev 15: 373-378, 2014.
6. Thanaprapasr D, Narthinanthar A, Likittanasombut P, Na Ayudhya N, Charakorn C, Udomsubpayakul U, Subhadarbandhu T and Wilailak S: Bone metastasis in cervical cancer patients over a 10-year period. Int J Gynecol Cancer 20: 373-378, 2010.
7. Hydalh RD, Schwartz LM and Clarkson PM: NF-κB activity functions in primary pericytes in a cell- and non-cell-autonomous manner to affect myofibre formation. Muscle Nerve 47: 522-531, 2013.
8. Lempert AS, Bai S, Narayan M, Wu J, Yoon SO, Carter BD and Lu QR: NF-κB forms a complex with the chromatin remodeler BRG1 to regulate Schwann cell differentiation. J Neurosci 33: 2388-2397, 2013.
9. Zhou R, Hu G, Gong AY and Chen XM: Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells. Nucleic Acids Res 38: 3222-3232, 2010.
10. Pfeffer LM: The role of nuclear factor kappaB in the interferon response. J Interferon Cytokine Res 31: 553-559, 2011.
11. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
12. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999.
13. Chen H, Ji R, Shao J, He C, Jin M and Xu Y: TLR4-MyD88-TRAF6-TAK1 Complex-Mediated NF-κB Activation Contribute to the Anti-inflammatory effect of V8 in LPS-induced human cervical cancer SiHa cells. Inflammation 39: 172-181, 2016.
14. Ma XF, Zhang J, Shuai HL, Guan BX, Luo X and Yan RL: IKKβ/NF-κB mediated the low doses of bisphenol A induced migration of cervical cancer cells. Arch Biochem Biophys 573: 52-58, 2015.
15. Pajukanta P, Lilja HE, Sinisheim JS, Cantor RM, Lusis AJ, Gentile M, Duan XJ, Soro-Paavonen A, Naukkarinen J, Saarela J, et al: Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36: 371-376, 2004.
16. Plaisier CL, Horvath S, Huertas-Vazquez A, Cruz-Bautista I, Herrera MF, Tusie-Luna T, Aguilar-Salinas C and Pajukanta P: A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. PLoS Genet 5: e1000642, 2009.

17. Meex SJ, van Vliet-Ostaptchouk JV, van der Kallen CJ, van Greevenbroek MM, Schalkwijk CG, Feskens EJ, Blaak EE, Wijmenga C, Hofker MH, Stehouwer CD and de Bruin TW: Upstream transcription factor 1 (USF1) in risk of type 2 diabetes: Association study in 2000 Dutch Caucasians. Mol Genet Metab 94: 352-355, 2008.

18. Benedet JL, Bender H, Jones H III, Ngan HY and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70: 209-262, 2000.

19. Coulson JM, Edgson JL, Marshall-Jones ZV, Mulgrew R, Quinn JP and Woll PJ: Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box. Biochem J 369: 549-561, 2003.

20. Chen B, Hsu R, Li Z, Kogut PC, Du Q, Rouser K, Camoretti-Mercado B and Solway J: Upstream stimulatory factor activates GATA5 expression through an E-box motif. Biochem J 446: 89-98, 2012.

21. Phane-Zeppenfeld J, Schroer N, Walch-Ruckheim B, Oldak M, Groter A, Hegde S and Smola S: Cervical cancer cell-derived interleukin-6 impairs CCR7-dependent migration of MMP-9-expressing dendritic cells. Int J Cancer 134: 2061-2073, 2014.

22. Sun S, Tang L, Zhang J, Lu F, Wang Z, Wang L, Zhang Q, Zheng C, Qiu L, Jia Z, et al: Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int J Nanomedicine 9: 2061-2073, 2014.

23. Xu L, Liu JH, Zhang J and Wang ZH: Blockade of autophagy aggravates endoplasmic reticulum stress and improves Paclitaxel cytotoxicity in human cervical cancer cells. Cancer Res Treat 47: 313-321, 2015.

24. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246, 2001.

25. Li J, Jia H, Xie L, Wang X, Wang X, He H, Lin Y and Hu L: Association of constitutive nuclear factor-kappaB activation with aggressive aspects and poor prognosis in cervical cancer. Int J Gynecol Cancer 19: 1421-1426, 2009.

26. Chou RH, Hsieh SC, Yu YL, Huang MH, Huang YC and Hsieh YH: Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-kB signaling pathway. PLoS One 8: e71983, 2013.

27. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pi L, Žarlo RJ, et al: NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13: 62-69, 2007.

28. Rhode J, Fogoros S, Zick S, Wahl H, Griffith KA, Huang J and Liu JR: Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement Altern Med 7: 44, 2007.

29. Zong H, Wang F, Fan QX and Wang LX: Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappaB signaling pathways. Mol Biol Rep 39: 4803-4808, 2012.

30. Sahu BD, Kumar JM and Sistla R: Fisetin, a dietary flavonoid, ameliorates experimental colitis in mice: Relevance of NF-kB signaling. J Nutr Biochem 28: 171-182, 2016.

31. Yuan Q, Bu Q, Li G, Zhang J, Cui T, Zhu R and Mu D: Association between single nucleotide polymorphisms of upstream transcription factor 1 (USF1) and susceptibility to papillary thyroid cancer. Clin Endocrinol (Oxf) 84: 564-570, 2016.

32. Landa I, Ruiz-Llorente S, Montero-Conde C, Inglada-Pérez L, Schiavi F, Leskela S, Pita G, Milne R, Maravall J, Ramos I, et al: The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet 5: e1000637, 2009.